(Q38072402)

28 August 2017

1 reference

title

Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistance (English)

1 reference

metastatic renal cell carcinoma

28 August 2017

1 reference

1 reference

Muhammad Khattak

1

1 reference

28 August 2017

James Larkin

series ordinal

2

1 reference

28 August 2017

publication date

8 January 2013

1 reference

28 August 2017

published in

World Journal of Urology

1 reference

28 August 2017

volume

32

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

19-29

1 reference

https://scigraph.springernature.com/pub.10.1007/s00345-012-1013-z

28 August 2017

exact match

0 references

cites work

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

21 January 2018

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Tumour evolution inferred by single-cell sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Chromosomal instability confers intrinsic multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Paradoxical relationship between chromosomal instability and survival outcome in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00345-012-1013-Z

Commentary on: "Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial." Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S, Escudier B. Bri

21 January 2018

1 reference

12 December 2020

Tumor heterogeneity: causes and consequences

1 reference

12 December 2020

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human p

1 reference

12 December 2020

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting

1 reference

12 December 2020

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity

1 reference

12 December 2020

EAU guidelines on renal cell carcinoma: the 2010 update

1 reference

12 December 2020

10.1007/S00345-012-1013-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1046886074

0 references

1 reference